The company had reported a robust operating performance for the second quarter ended September 2013 and had also received the final approval from the U.S. health regulator to manufacture and market DuloxetineHydrochloride Delayed-Release capsules, an anti-depressant drug, in the American market.
Continuing its gaining momentum, shares of company gained as much as 5.47 per cent to trade at Rs 404.80 a piece on the BSE.
In a similar fashion, shares of the company advanced 4.43 per cent 400.80 a piece on National Stock Exchange.
Meanwhile, the broader benchmark Sensex was quoting at 21,124.39, down 23.36 points or 0.11 per cent at 10:12 hours.
Dion Global Solutions Ltd.
